Pieris Pharmaceuticals, Inc.

NASDAQ:PIRS

13.6 (USD) • At close December 13, 2024
Bedrijfsnaam Pieris Pharmaceuticals, Inc.
Symbool PIRS
Munteenheid USD
Prijs 13.6
Beurswaarde 17,955,264
Dividendpercentage 0%
52-weken bereik 6.2 - 22.32
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stephen S. Yoder J.D.
Website https://www.pieris.com

An error occurred while fetching data.

Over Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes

Vergelijkbare Aandelen

Genenta Science S.p.A. logo

Genenta Science S.p.A.

GNTA

4.237 USD

Graphite Bio, Inc. logo

Graphite Bio, Inc.

GRPH

3.18 USD

ImmunoPrecise Antibodies Ltd. logo

ImmunoPrecise Antibodies Ltd.

IPA

0.46 USD

Apyx Medical Corporation logo

Apyx Medical Corporation

APYX

1.43 USD

ORIC Pharmaceuticals, Inc. logo

ORIC Pharmaceuticals, Inc.

ORIC

9.91 USD

Gritstone bio, Inc. logo

Gritstone bio, Inc.

GRTS

0.032 USD

CorMedix Inc. logo

CorMedix Inc.

CRMD

11.22 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)